Stay updated with breaking news from Benevolent Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective
This release may contain forward-looking statements. Forward-looking statements are statements that are not...
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target - AI-generated target was identified through The Benevolent Platform and AstraZeneca's scientific expertise and rich datasets LONDON, Jan. 27, 2021 /PRNewswire/ -- BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company's portfolio. The Benevolent Platform predicted this nove...